JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 38 No. 8 1208-1210
© 1997 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Shirbiny, A. M.
Right arrow Articles by Larson, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Shirbiny, A. M.
Right arrow Articles by Larson, S. M.

Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma

Ayda M. El-Shirbiny, Henry Yeung, Massimo Imbriaco, Joseph Michaeli, Homer Macapinlac and Steven M. Larson

Nuclear Medicine Section, Departments of Radiology and Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints: Ayda M. El-Shirbiny, MD, PhD, Nuclear Medicine Section, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

ABSTRACT

Experience of scintigraphic detection of bone lesion and active bone marrow involvement of multiple myeloma, especially with sestamibi and FDG-PET scans is in evolution. We report a case of intense sestamibi uptake in bone marrow correlating with the extent of the disease, while FDG-PET scans showed activity only in areas of active disease progression associated with pain. Technetium-99m-sestamibi appears to indicate the extent of the disease, while [18F]FDG-PET scans show sites of active tumor proliferation and may be useful in directing local therapy such as radiation.

Key Words: multiple myeloma • sestamibi • fluorine-18-FDG • PET




This article has been cited by other articles:


Home page
 JNMHome page
R. Fonti, B. Salvatore, M. Quarantelli, C. Sirignano, S. Segreto, F. Petruzziello, L. Catalano, R. Liuzzi, B. Rotoli, S. Del Vecchio, et al.
18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
J. Nucl. Med., February 1, 2008; 49(2): 195 - 200.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Even-Sapir
Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Koutsikos, T. Athanasoulis, A. Anagnostopoulos, A. Velidaki, M. Passadi, M. A. Dimopoulos, and C. Zerva
Combined Use of 99mTc-Sestamibi and 99mTc-V-DMSA in the Assessment of Chemotherapy Effectiveness in Patients with Multiple Myeloma
J. Nucl. Med., June 1, 2005; 46(6): 978 - 982.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. J. C. Angtuaco, A. B. T. Fassas, R. Walker, R. Sethi, and B. Barlogie
Multiple Myeloma: Clinical Review and Diagnostic Imaging
Radiology, April 1, 2004; 231(1): 11 - 23.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. G.M. Durie, A. D. Waxman, A. D'Agnolo, and C. M. Williams
Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
J. Nucl. Med., November 1, 2002; 43(11): 1457 - 1463.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1997 by the Society of Nuclear Medicine.